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ABSTRACT   1 
Objectives  2 
To evaluate the association between zolpidem use and the risk of Alzheimer’s disease 3 
among older people. 4 
Design 5 
A retrospective cohort study using data from 2001 to 2011 from the National Health 6 
Insurance Research Database. 7 
Setting 8 
Taiwan. 9 
Participants 10 
A total of 6,922 patients aged 65 years or older enrolled from January 2002 to 11 
December 2004 (the enrollment period). 12 
Intervention (exposure) 13 
1) Zolpidem users were identified as patients who used zolpidem during the 14 
enrollment period. The index date was the date of the first zolpidem prescription. 15 
2) Dosage of zolpidem use was defined using cumulative defined daily dose (cDDD) 16 
based on the cumulative dosage that patients took within one year after the index 17 
date (grouped as: less than 28, 28-90, 91- 180, and more than 180 cDDD). 18 
Measurements 19 
The occurrence of Alzheimer’s disease was defined as the time period from the end of 20 
one year after the index date to the date of the Alzheimer’s disease diagnosis. The 21 
propensity score was used to adjust the measured confounders of Alzheimer’s disease. 22 
Cox proportional hazards models were used to evaluate the association between 23 
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zolpidem use and the incidence of Alzheimer’s disease.  24 
Results 25 
Zolpidem users with a high cumulative dose (>180 cDDD) in the first year after 26 
initiation had a significantly greater risk of Alzheimer’s disease than non-zolpidem 27 
users (HR= 2.97, 95% CI=1.61-5.49) and low cumulative dose (< 28 cDDD) users 28 
(HR= 4.18, 95% CI=1.77-9.86).  29 
Conclusion 30 
We found the use of a high cumulative dose of zolpidem was associated with an 31 
increased risk of Alzheimer’s disease among older people living in Taiwan. It is 32 
advised to use caution when considering long-term use of zolpidem in older patients. 33 
 34 
Key Words: zolpidem, Alzheimer’s disease, hypnotics, National Health Insurance 35 
Research Database (NHIRD), Taiwan 36 
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INTRODUCTION   1 
Dementia is a global health burden.1,2 According to a recent report in 2015 from 2 
the World Health Organization, there are 47.5 million people living with dementia 3 
worldwide, and over 60% of dementia cases are caused by Alzheimer’s disease (AD).3 4 
With a global aging population, the total number of people with AD or dementia is 5 
expected to significantly increase over the next 10 years.4-6 In 2010, the total global 6 
costs of dementia was US$ 604 billion, and the amount will increase by 85% between 7 
2010 to 2030.7  8 
Zolpidem, a non-benzodiazepine hypnotic, is often used for short-term treatment 9 
of insomnia.8-11 It remains one of the most commonly prescribed hypnotics due to the 10 
advantages of quick onset and less residual effects.10-12 The pharmacologic 11 
mechanisms of zolpidem including anxiolytic, muscle relaxant, sedative, and 12 
anticonvulsant effects were found to be working throughα1, 2, 3 and 5 subunits of 13 
gamma-amino-butyric acid type A (GABAA) receptors.13 Unlike benzodiazepines, 14 
zolpidem has high-affinity binding to the α1 subunit, which provides more specific 15 
sedative properties than benzodiazepines.13  16 
Previous studies reported that both benzodiazepine and zolpidem use are 17 
associated with memory loss and a decline in the cognitive function.14,15 A link 18 
between benzodiazepine use and dementia is well documented.16-19 Benzodiazepines 19 
inhibit neurotransmitter in the brain through acting on receptors of γ aminobutyric 20 
acid A and have been hypothesized to increase the development of AD.17 Although 21 
zolpidem has fewer benzodiazepines-like adverse effects, taking zolpidem may still be 22 
associated with an increased risk of cognitive and psychomotor decline, eventually 23 
resulting in a long-term memory loss.4    24 
A limited number of studies have investigated the association between zolpidem 25 
use and dementia. A recent case-control study reported that zolpidem use was 26 
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associated with an increased risk of dementia.20 Studies have reported the association 27 
between the cumulative dose-response of benzodiazepines use and the risk of dementia 28 
or AD.21 Whether zolpidem use has the same dose-response effects as benzodiazepine 29 
requires further investigation. It also remains unclear whether zolpidem use is 30 
associated with an increased risk of developing AD. Therefore, the purpose of this 31 
study was to evaluate the association between zolpidem use and the risk of AD among 32 
older patients in Taiwan. We hypothesized that zolpidem users would have a higher 33 
risk of being diagnosed with AD than non-zolpidem users. Furthermore, we 34 
hypothesized that higher cumulative doses of zolpidem use would have a greater 35 
association with being diagnosed with AD compared to lower cumulative dose or not 36 
having been exposed to zolpidem at all.  37 
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METHODS 
Data source 38 
This was a retrospective cohort study based on data from the National Health 39 
Insurance Research Database (NHIRD). A single-payer National Health Insurance 40 
(NHI) program was implemented in Taiwan in 1995, and currently up to 99.9% of the 41 
23 million Taiwanese residents were enrolled in this program.22-24 The NHIRD, which 42 
is an administrative claims database containing registration files, patient identification 43 
files, and medical claims files (including inpatient records, ambulatory care records, 44 
and prescription files), is generated by the National Health Insurance Administration 45 
and regularly maintained by the Taiwan National Health Research Institutes.22-24 We 46 
used the 2010 Longitudinal Health Insurance Database (LHID 2010) which contains 47 
data of one million Taiwanese beneficiaries in 2010 randomly selected from the 48 
NHIRD.22-24 Overall, 11 years of data were included, from January 1, 2001 to 49 
December 31, 2011. 50 
Study population and study design  51 
We defined the enrollment period from January 1, 2002 to December 31, 2004 to 52 
select patients who were aged 65 years or older. We used the new user design to conduct 53 
this study. To be considered as new users, patients had to have had at least one 54 
prescription of zolpidem during the enrollment period and the initial prescription (the 55 
first prescription) needed to have been written for a quantity equal to at least a 7-day 56 
supply. The date of the first zolpidem prescription was defined as the index date. 57 
Zolpidem users were further required to be free of zolpidem or other non-BZD drugs 58 
(including zolpiclone, zaleplon and eszopiclone) within one year before the index date 59 
(i.e., pre-index period). Patients who were not qualified as users of zolpidem were 60 
considered as non-zolpidem users. 61 
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We further excluded patients if they had ever been diagnosed with AD (the 62 
International Classification of Disease, 9th Revision, Clinical Modification [ICD-9-CM] 63 
code, 331.0) or any other type of dementia (290.0, 290.1, 290.2, 290.3, 290.4, 294.1, 64 
331.1, 331.2) at the index date or during the pre-index period. Patients with any records 65 
of cognitive impairment (331.8, 331.83, and 331.9), Huntington's disease (333.4) and 66 
Creutzfeldt–Jakob disease (046.11, 046.19) at the pre-index period were excluded. 67 
Moreover, patients with any medication treatment for dementia (donepezil, 68 
rivastigmine, galantamine and memantine) on the index date or in the pre-index period 69 
were excluded.  70 
The follow-up period started on one year after the index date to account for the 71 
induction period and continued for 6 years. Considering that Alzheimer’s disease is a 72 
progressive degenerative disease and that the effect of zolpidem may require a period of 73 
time to manifest, a one-year induction period after the index date was set to prevent a 74 
reverse causality bias. Figure 1 showed the details of the enrollment process.  75 
Exposure 76 
The primary exposure was the use of zolpidem, defined as at least one zolpidem 77 
prescription written for a minimum supply to cover seven days of consecutive 78 
zolpidem prescription filled since the index date. Using the rule of having a minimum 79 
of seven day supply of drug was to prevent mis-assigning patients who used zolpidem 80 
only occasionally or a few days to be classified as zolpidem users. Overall, patients 81 
were categorized into two groups as follows:  82 
(i) Zolpidem users: patients with at least one prescription written for a quantity of a 83 
minimum of seven day supply. The initial prescription that met this criteria was 84 
considered the index prescription and the date it was dispensed was considered the 85 
index date. 86 
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(ii) Non-zolpidem users: patients without any zolpidem prescription records or who 87 
received zolpidem prescriptions written for a quantity smaller than a seven day 88 
supply during the induction period.  89 
Each zolpidem user was matched up to one non-user on age and sex. The matched 90 
nonusers were assigned the same index date as the new user of zolpidem. Non-users 91 
were also required to be free of zolpidem or other non-BZD drugs during the pre-index 92 
period to avoid bias from the prevalent users. 93 
We also studied the cumulative exposure of zolpidem use, which was measured in 94 
the unit of defined daily dose (DDD) that has been recommended by WHO.25 The DDD 95 
was defined as the average maintenance dose of a medication per day for the major 96 
indication in one adult.25 The DDD of zolpidem was 10 mg. To obtain the cumulative 97 
DDD (cDDD) for each patient, we summed all the zolpidem doses prescribed during a 98 
defined period (i.e., one year after index date) and then convert the quantity to the 99 
number of DDD.26 According to the cDDD of zolpidem during the exposure period, all 100 
the zolpidem users were categorized into four groups: less than 28, 28-90, 91- 180, and 101 
more than 180 cDDD.  102 
Study outcomes 103 
The outcome was the occurrence of AD which was defined as the time to the first 104 
diagnosis of AD (331.0). The diagnosis was restricted to be made by a neurologist or a 105 
psychiatrist to ensure the validity of the diagnosis. It was measured from the end of the 106 
induction period to the date of the AD diagnosis or to the date of censoring. Patients 107 
with a prior diagnosis of AD were excluded. Patients were censored at the earliest date 108 
of insurance withdrawal, death, or the end of the six-year follow-up period. All the 109 
diagnoses of AD were measured in the six years after the induction period in two 110 
groups.   111 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Covariates 112 
In addition to age and sex, covariates included condition-related variables and 113 
medication-related variables. Condition-related variables included hypertension 114 
(401.0, 401.1, 401.9, 402.0, 402.1, 402.9, 403.0, 403.1, 403.9, 404.0, 404.1, and 404.9), 115 
stroke (431, 432.0, 432.1, 432.9,433, 434, 436, and 437), myocardial infarction (410 116 
and 412), hypercholesterolemia (272.0), diabetes mellitus (250), depression (296.2, 117 
296.3, 300.4, and 311), anxiety (300), psychotic-related disorder (295, 297, and 298), 118 
alcohol-related disorder (291, 303, 357.5, 425.5, 535.3, 571.0, 571.1, 571.2, and 571.3), 119 
sleep disorder (307.4 and 780.5), Parkinson’s disease (332.0) and head injury (800-804, 120 
850-854 and 959.01).21,27-29 The above conditions were included because previous 121 
studies have reported that these conditions were potential risk factors for the 122 
development of AD.21,27-29 Medication-related variables included drug classes of 123 
antihypertensive drugs, anti-diabetic medication, anticoagulants, anti-hyperlipidemia 124 
drugs, antidepressants, benzodiazepines (BZDs), anti-Parkinson medication and 125 
antipsychotics. All covariates were identified during the pre-index period. In addition, 126 
we further included mental health-related physician visits as one additional covariate 127 
because mental illnesses were considered to have a high association with the 128 
development of AD.30,31 We calculated the total number of outpatient and emergency 129 
visits for neurology and psychiatry clinics in the pre-index period. The variable was 130 
categorized into 4 groups by the number of the visits (less than 6, 6-10, 11-15, and 131 
more than 15 visits). 132 
 133 
Statistical Analysis 134 
Propensity score matching was used to balance the measurable confounders 135 
between zolpidem users and non-zolpidem users.32,33 For each patient, we estimated 136 
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the probability of receiving zolpidem (i.e., the propensity score, PS), using a logistic 137 
regression model including all variables presented in the previous section. We then 138 
used a greedy 5-to-1 digit matching algorithm without replacement to match each 139 
zolpidem user with one nonuser of zolpidem on the propensity score.33 The matching 140 
process started with the first 5 significant figures of the propensity score, moved to 141 
the first 4 significant figures, and so forth. Zolpidem users who had no match to at 142 
least 1 decimal place were excluded. Matching helped to minimize the likelihood that 143 
any differences in patient outcome observed were due to the zolpidem use other than 144 
confounders. The baseline characteristics of the study population before and after 145 
propensity score matching were described with descriptive statistics. The Student’s 146 
t-test and chi-square test were used to compare patient characteristics. Time to event 147 
analysis was performed using the Cox proportional hazards model to estimate the 148 
relative hazards of AD comparing zolpidem users to nonusers. 149 
Sensitivity analysis 150 
We further conducted two sensitivity analyses. The first sensitivity analysis was 151 
to vary the length of the exposure period from one year to two years to take into 152 
account the effect of the longer zolpidem exposure. Both groups were followed five 153 
years after the two-year exposure period. The cumulative dose of the zolpidem use 154 
was calculated during the two-year exposure period. In addition, the second 155 
sensitivity analysis was to include the AD diagnosis given by any practitioners instead 156 
of the diagnosis only given by a psychiatrist or neurologist in the main analysis.    157 
SAS® proprietary Software, Release 9.3 (SAS institute Inc., Cary, NC)34 was used 158 
for all the analysis in this study. A two-sided P value (P<0.05) was used to determine 159 
statistical significance. This study was reviewed and approved by the Taipei Medical 160 
University Joint Institutional Review Board (TMU-JRIB) in May 2015. 161 
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RESULTS 162 
Table 1 shows the baseline characteristics of the study population before and after 163 
propensity score matching. A total of 11,318 patients were identified before matching. 164 
The mean age of the study population was 72.1 years old and 62.1% patients were 165 
female. More zolpidem users had the diagnoses of hypertension, stroke, myocardial 166 
infarction, hypercholesterolemia, diabetes mellitus, depression, anxiety, 167 
psychotic-related disorder, alcohol-related disorder, sleep disorder, Parkinson’s disease, 168 
and head injury. Moreover, a significantly higher proportion of zolpidem users used 169 
other medications when compared with non-zolpidem users. After propensity score 170 
matching, there were 3,461 zolpidem users and 3,461 non-users. All the covariates 171 
except the use of anti-Parkinson medication (P < 0.05) were balanced between the two 172 
groups.  173 
Table 2 shows the incident rates and follow-up time among the study population. 174 
During the six-year follow-up period, 75 patients developed AD, which included 43 175 
(1.2%) patients among the zolpidem users and 32 (0.9%) among the non-zolpidem 176 
users. Among zolpidem users, 71% (2,457) of the users took zolpidem under 90 177 
cDDD during the first year following the index date (35.2%, <28 cDDD and 35.8%, 178 
28-90 cDDD). About 16% (553) of the users were in the >180 cDDD group. The 179 
six-year incidence of developing AD among zolpidem users was 0.7% for the <28 180 
cDDD group, 1.2% for the 28-90 cDDD group, 1.1% for the 91-180 cDDD group, and 181 
2.7% for the >180 cDDD group. The mean follow-up time was 5.97 years for 182 
zolpidem users and 5.98 years for non-zolpidem users.   183 
   Table 3 shows the results of the Cox proportional hazards regression model. The risk 184 
of developing AD for zolpidem users compared with non-users was not significantly 185 
higher [hazard ratio (HR) =1.35, 95% CI= 0.85-2.13]. However, zolpidem users with 186 
more than 180 cDDD in a year had an increased risk of developing AD than the users 187 
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with less than 28 mg cDDD (HR=4.18, 95% CI =1.77-9.86) and non-zolpidem users 188 
(HR=2.97, 95% CI =1.61-5.49).   189 
Results from the sensitivity analyses (Supplementary Table S1, Supplementary 190 
Table S2) showed the similarity of the results in the main analysis. In the first 191 
sensitivity analysis that evaluated the effect of the longer zolpidem exposure on the 192 
risk of AD, zolpidem users with more than 180 mg cDDD were found to have a 193 
higher hazard of developing AD when compared with users with less than 28 mg 194 
cDDD (HR=3.27, 95% CI =1.57-6.80) and non-zolpidem users (HR=3.25, 95% CI 195 
=1.70-6.20). In the second sensitivity analysis when including AD diagnosis given by 196 
all practitioners instead of the diagnosis only given by a psychiatrist or neurologist, 197 
zolpidem users with a high cumulative dosage were significantly associated with a 198 
higher risk of developing AD compared to non-users (HR =1.93, 95% CI= 1.05-3.54). 199 
However, we did not find a difference in the risk of developing AD between zolpidem 200 
users and non-users (HR =1.27, 95% CI= 0.84-1.93).  201 
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DISCUSSION 202 
To our knowledge, this is the first observational study using a retrospective 203 
cohort study design to evaluate the association between the use of zolpidem and the 204 
risk of AD among older patients. Patients with a high cumulative dose of zolpidem had 205 
a significantly higher risk of developing AD when compared with patients with a low 206 
cumulative dose of zolpidem within one year. 207 
Previous studies have found that the use of hypnotics was associated with an 208 
increased risk of dementia and AD.16-19,21 Nonetheless, in those studies, the exposure 209 
of hypnotics was defined as a mixed use of benzodiazepine hypnotics and 210 
non-benzodiazepine hypnotics,16,17,19,21,35 or benzodiazepine hypnotics only.21 In 211 
contrast to the previous studies, our findings provide a new perspective in that we 212 
found zolpidem (a non-benzodiazepine hypnotic), taken by patients in higher doses 213 
(high cumulative dose), was associated with an increased risk of AD. Contrary to 214 
previous studies,28,35 this study further assessed the effects of cumulative exposure of 215 
zolpidem on the risk of AD. This is an advantage because our study provided clinical 216 
evidence of an association between the cumulative dose effect of zolpidem use and the 217 
diagnosis of AD. Our study showed no increased risk of developing AD in zolpidem 218 
users when compared to non-users. However, we found that high cumulative dose 219 
(>180 cDDD) within the first year after initiation was associated with a higher risk of 220 
developing AD, compared with low cumulative dose (<28 cDDD) or non-use of 221 
zolpidem. Our findings indicate that zolpidem was not associated with the risk of AD in 222 
older population but there is possibility of an increased risk of AD with high 223 
accumulative dose of zolpidem. Future studies are warranted to examine the risk of AD 224 
after long-term use or high dose of zolpidem. 225 
 Moreover, compared to previous studies using claims data,19,28,35 our study had a 226 
relatively long follow-up period which enhances the ability to observe the occurrence 227 
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of AD. With a long follow-up period and mainly focusing on the effect of 228 
non-benzodiazepine hypnotic use, our study provides a comprehensive investigation 229 
with results that inform health care providers of the need to be aware that higher 230 
cumulative doses of zolpidem are associated with an increased risk of dementia 231 
among older people within one year. 232 
Our study is a retrospective cohort study with new user design36,37 which 233 
mitigated biases and increased the study validity to better evaluate the association 234 
between the use of zolpidem and the increased risk of dementia when compared to 235 
previous studies conducted mainly using a nested case-control study design.16,19,20,28 236 
In addition, our study further confirmed that zolpidem users with higher cumulative 237 
doses had an increased risk of AD than lower dose users as well as non-zolpidem 238 
users. We ensured the temporal sequence between the exposure (zolpidem use) and 239 
the outcome (development of AD) was properly placed. For example, the one-year 240 
induction period we used was to minimize the bias of reverse causation.36 Cases of 241 
AD which occurred during the induction period were not included as the outcome of 242 
this study.  243 
Furthermore, we used propensity score to match the baseline characteristics 244 
between zolpidem users and non-zolpidem users. We found the overall health status of 245 
the non-zolpidem users was better than the users. The unbalance between exposure 246 
groups that is commonly observed in pharmacoepidemiological studies could cause 247 
confounding by indication bias and threaten the validity of the study.32,33 The 248 
propensity score matching approach minimized the difference of characteristics and 249 
resulted in a more robust estimation.  250 
Although the mechanism of the effect of zolpidem use on dementia remains 251 
unknown, a plausible pathway is through affecting calcium signaling of Cornu 252 
Ammonis 1 (CA1) hippocampal neurons. An animal study showed zolpidem may  253 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
reduce the neuronal activity in the hippocampus, a crucial part of the brain for normal 254 
cognitive function and formation of new memories.4 The effects of cumulative doses of 255 
zolpidem might cause continuing depressive effects on the hippocampus, and 256 
eventually reduce the cognitive function and cause memory loss. Furthermore, similar 257 
to benzodiazepines, zolpidem has a similar mechanism of action as benzodiazepines 258 
acting on the binding site of GABAA 13 receptors.  With a similar pharmacologic 259 
implication, high cumulative doses of zolpidem could impair cognitive ability and 260 
lead to an increased risk for development of AD. 261 
A high prevalence of zolpidem use was found in our study. About 15% of the 262 
older people in Taiwan were prescribed zolpidem during the study period. In addition, 263 
treatment with higher doses over long periods of time (high cumulative dose) was 264 
observed once treatment was started. For example, more than 15% of the new users 265 
had cumulative doses beyond 180 cDDD of zolpidem in one year. We also found a 266 
high prevalence of benzodiazepine use in both zolpidem user and non-zolpidem user 267 
groups. In Taiwan, the use of benzodiazepine is prevalent among older patients.38 A 268 
high prevalent benzodiazepine use could further lower the cognitive function among 269 
older patients with AD because previous studies have reported a positive association 270 
between the benzodiazepine use and the occurrence of AD.16-19,21    271 
 Inadequate management of sleep disorders among older patients in clinical 272 
practice is often unrecognized.39 Unprecedented rates of adverse drug events could 273 
still occur among older zolpidem users due to the high prevalence and high 274 
cumulative dose of zolpidem use found in our study. It could also result in an overuse 275 
of zolpidem among these individuals. Due to the risk of zolpidem use among older 276 
patients, the most updated 2015 American Geriatrics Society (AGS) Beers Criteria for 277 
Potentially Inappropriate Medication Use in Older Adults has suggested that older 278 
patients should avoid any use of zolpidem when treating insomnia.40 Therefore, a 279 
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careful assessment of zolpidem use among older patients is necessary before zolpidem 280 
is initiated.39  281 
Our study has several limitations. First, no clinical data such as clinical 282 
presentation, medical histories, neurological examinations, images, and biomarkers 283 
were available in our study.41 These data are often used to diagnose AD. Identifying 284 
patients only using ICD-9 CM codes may not be valid enough. Misclassification and 285 
under-coding of AD remained possible.42,43 Second, the database does not contain 286 
information on socioeconomic status, health lifestyle, and physical activities, which are 287 
also risk factors for AD.44 The possible confounding effects of these unmeasurable risk 288 
factors were unable to be eliminated in our study. Third, due to the length of available 289 
data, we only included patients with at least six years of follow-up time, which could 290 
possibly underestimate the risk of dementia. Fourth, although the propensity score 291 
matching mostly eliminated the unbalanced measured confounders between the 292 
zolpidem-user and non-user groups, the residual confounding by unmeasured variables 293 
such as the presence of unmeasured comorbidities, disease severity, and over the 294 
counter medication use could exist. Unbalanced comparison groups may still affect the 295 
risk estimation and lower the study validity. Fifth, we set a one-year induction period in 296 
the main analysis and two-year induction period in the sensitivity analysis to prevent 297 
the bias from reverse causation. However, due to the nature of the disease condition like 298 
dementia which could have a gradual onset or be underdiagnosed for several years, the 299 
short induction period may still not completely eliminate the bias. Sixth, since all 300 
physicians can make an AD diagnosis in Taiwan, only patients with an AD diagnosis 301 
made by a psychiatrist or neurologist were counted so as to increase the outcome 302 
specificity. (Supplementary Table S9 described the number of psychiatrist/neurologist 303 
visits during the follow-up period between zolpidem user and nonuser groups.) 304 
However, this restriction could become a potentially important source of detection bias 305 
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as zolpidem users could be more likely to see these specialists and thus have a higher 306 
chance to receive an early diagnosis of AD. The restriction could also led to a 307 
population of patients with more severe AD, while undercounting those with milder 308 
onset of symptoms. Finally, patterns of zolpidem use identified from administrative 309 
claims data may overestimate the real consumption of zolpidem because a 310 
prescription refilled may not mean a prescription was taken. However, previous 311 
studies have shown the use of claims data was a relatively valid measurement of 312 
prescription use patterns.45,46 313 
In conclusion, health care providers need to be mindful when prescribing 314 
zolpidem to older patients. A routine evaluation of older zolpidem users is necessary, 315 
especially for those with chronic insomnia. In order to lower the dependence with the 316 
medication, non-pharmacologic intervention such as the cognitive behavior therapy 317 
can be considered for older patients who use zolpidem. 318 
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Figure 
Figure 1. The identification process of the study population and the classification of 
zolpidem and non-zolpidem users 
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TABLES 
Table 1.  Baseline characteristics of the study population before and after propensity score matching 
 Before propensity score matching  N=11,318   After propensity score matching  N=6,922 
Characteristic Study population 
(N=11,318) 
Zolpidem use 
(N=5,659) 
Non-zolpidem 
use (N=5,659) 
P  
value 
  Study population 
(N=6,922) 
Zolpidem use 
(N=3,461) 
Non-zolpidem 
use (N=3,461)  
P  value 
  
N % N % N %    N % N % N %   
Age (mean, SD) 72.1 5.33 72.1 5.33 72.1 5.33 1.00  72.1 5.33 72.0 5.41 72.2 5.24 0.34 
Sex                
  Female 7,028 62.1 3,514 62.1 3,514 62.1   4,351 62.9 2,116 61.1 2,235 64.6  
  Male 4,290 37.9 2,145 37.9 2,145 37.9 1.00  2,571 37.1 1,345 38.9 1,226 35.4 1.00 
Covariates                
  Hypertension 6,036 53.3 3,557 62.9 2,479 43.8 <0.01  3,970 57.4 2,006 58.0 1,964 56.7 0.30 
  Stroke 1,466 13.0 995 17.6 471 8.3 <0.01  851 12.3 424 12.3 427 12.3 0.91 
  Myocardial infarction 146 1.3 109 1.9 37 0.7 <0.01  73 1.1 36 1.0 37 1.1 0.91 
  Hypercholesterolemia 2,252 19.9 1,390 24.6 862 15.2 <0.01  1,424 20.6 712 20.6 712 20.6 1.00 
  Diabetes mellitus 2,246 19.8 1,366 24.1 880 15.6 <0.01  1,450 20.9 736 21.3 714 20.6 0.52 
  Depression 486 4.3 403 7.1 83 1.5 <0.01  164 2.4 82 2.4 82 2.4 1.00 
  Anxiety 1,769 15.6 1,288 22.8 481 8.5 <0.01  945 13.7 477 13.8 468 13.5 0.75 
  Psychotic-related disorder 83 0.7 65 1.1 18 0.3 <0.01  35 0.5 17 0.5 18 0.5 0.87 
  Alcohol-related disoeder 32 0.3 24 0.4 8 0.1 <0.01  18 0.3 12 0.3 6 0.2 0.16 
  Sleep disorder 2,297 20.3 1,786 31.6 511 9.0 <0.01  1,051 15.2 540 15.6 511 14.8 0.33 
  Parkinson disease 156 1.4 113 2.0 43 0.8 <0.01  76 1.1 38 1.1 38 1.1 1.00 
  Head Injury 264 2.3 169 3.0 95 1.7 <0.01  163 2.4 80 2.3 83 2.4 0.81 
  AntiHTN 7,106 62.8 4,155 73.4 2,951 52.1 <0.01  4709 68.0 2,340 67.6 2,369 68.4 0.45 
  AntiDM 1,786 15.8 1,081 19.1 705 12.5 <0.01  1176 17.0 600 17.3 576 16.6 0.44 
  Anticoagulant 2,819 24.9 1,786 31.6 1,033 18.3 <0.01  1740 25.1 861 24.9 879 25.4 0.62 
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  Antilipidemia 1,624 14.3 992 17.5 632 11.2 <0.01  1055 15.2 522 15.1 533 15.4 0.71 
  Antidepressant 1,114 9.8 852 15.1 262 4.6 <0.01  501 7.2 251 7.3 250 7.2 0.96 
  BZD 6,221 55.0 4,121 72.8 2,100 37.1 <0.01  4016 58.0 2,007 58.0 2,009 58.0 0.96 
  AntiPD 412 3.6 274 4.8 138 2.4 <0.01  194 2.8 82 2.4 112 3.2 0.03* 
  Antipsychotics 1,402 12.4 930 16.4 472 8.3 <0.01  772 11.2 380 11.0 392 11.3 0.65 
 Outpatient visits due to mental disorder               
  < 6 times 1,478 13.1 1,004 17.7 474 8.4 <0.01  857 12.4 423 12.2 434 12.5 0.69 
  6-10 times 396 3.5 269 4.8 127 2.2 <0.01  220 3.2 107 3.1 113 3.3 0.68 
  11-15 times 260 2.3 188 3.3 72 1.3 <0.01  126 1.8 61 1.8 65 1.9 0.72 
  > 15 times 96 0.8 70 1.2 26 0.5 <0.01  47 0.7 21 0.6 26 0.8 0.46 
*P<0.05                
Note: Baseline characteristics (age and sex) by cDDD exposure categories were listed in the Supplementary Table S3 
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Table 2. Incidence of Alzheimer's disease (AD) between zolpidem users and nonusers 
from 2006 to 2011 by cumulative defined daily doses (cDDD)# in one year since the 
initiation 
 
Study group Number of AD         Follow-up (years) 
Exposures      n % n % Total  Mean 
Non-zolpidem use  3,461 100.0 32 0.9            20,703 5.98 
Zolpidem use 3,461 100.0 43 1.2            20,660 5.97 
By zolpidem cumulative  
dosage in one year since  
the initiation 
     Non-user      3,461 100.0 32 0.9            20,703 5.98 
     <28 cDDD      1,217 35.2 8 0.7              7,282 5.98 
     28-90 cDDD      1,240 35.8 15 1.2  7,414 5.98 
     91-180 cDDD       451 13.0 5 1.1              2,690 5.97 
     >180 cDDD         553 16.0 15 2.7              3,274 5.92 
#
 DDD was defined as the average maintenance dose of zolpidem use per day for the major indication in one adult.  
 The DDD of zolpidem was 10 mg. The cDDD was to add on the amount of zolpidem use per person in on year.  
Note: Results from incidence of all types of dementia were listed in the Supplementary Table S4 
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Table 3. The association between zolpidem use and the risk of Alzheimer's 
disease (AD): results of Cox proportional hazard regression models  
 
Study group Hazard ratio (95% CI) 
Non-zolpidem use (n=3,461) Reference Reference 
Zolpidem use  (n=3,461) 1.35 (0.85-2.13) 
By zolpidem cumulative dosage in one year since initiation 
     Non-user   Reference Reference 
     <28 cDDD  0.71 (0.32-1.54) 
     28-90 cDDD 1.31 (0.71-2.42) 
     91-180 cDDD   1.20 (0.47-3.09) 
     >180 cDDD  2.97 (1.61-5.49) 
Zolpidem users 
     < 28 cDDDs  Reference Reference 
     28-90 cDDDs 1.84 (0.78-4.34) 
     91-180 cDDDs   1.69 (0.55-5.17) 
     >180 cDDDs  4.18 (1.77-9.86) 
Note 1: Results from the risk of all types of dementia were listed in the Supplementary Table S5 
Note 2: Results from a trend analysis of the association between the increased exposure of zolpidem use and risk of 
Alzheimer’s disease were listed in the Supplementary Table S6 
Note 3: Results from the association between zolpidem use and risk of AD by sex (Supplementary Table S7) and age 
(Supplementary Table S8) showed the same results with the main analysis  
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1 
Patients aged ≥ 65 between January 1, 2002 and December 31, 
2004. N = 70,514  
Patients had been prescribed zolpidem at aged ≥ 65. 
N=10,354 (15%) 
Patients had been prescribed 
zolpidem and other non-BZDs 
before the index date. 
N=1,895 
Patients had been diagnosed or 
treated as any types of dementia. 
N=255 
Zolpidem user not matched to 
any non-exposed individual. 
N = 1  
N=8,459 
N=8,204 
Patients had not been prescribed zolpidem. 
N=61,924  
N=61,922 
Patients with invalid sex 
category. 
N= 2 
Patients had zolpidem prescription of ≤7 
days. 
N=1,764 
N=6,440 
N=5,659 N=5,659 
N=3,461 N=3,461 
N=5,660 
Patients had left from the medical 
insurance during the enrollment 
period N=780 
N=55,850 
Patients had left from 
the medical insurance. 
N=6,072 
Matching with age and sex ( 1:1 ) 
Propensity score matching 
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